Genomate provides computational intelligence software to analyze a cancer patient's unique molecular profile and tumor alterations. This analysis predicts responses to multiple targeted therapies, enabling oncologists to select optimal, personalized treatment plans. The platform delivers data-backed reports to improve treatment outcomes and efficiency in precision oncology.
Funding
$2.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Oncologists face challenges in selecting the most effective targeted therapies for cancer patients due to the complexity of tumor-specific molecular profiles. Current treatment approaches often focus on a limited number of genetic mutations, potentially overlooking other critical alterations that influence drug response. This can lead to suboptimal treatment decisions and reduced patient outcomes.
Solution
Genomate Health offers a computational intelligence platform that analyzes individual cancer patients' unique tumor profiles to identify optimal targeted therapies. By considering the complex interplay of genetic alterations and biomarkers, Genomate predicts responses to multiple therapies with high accuracy. The platform generates a comprehensive, data-backed report that empowers oncologists to make informed, personalized treatment decisions. This approach increases the likelihood of positive patient responses and improves median progression-free survival compared to treatments selected without Genomate's analysis.
Target Audience
Genomate's primary customers are oncologists, biopharma companies, and healthcare organizations seeking to improve cancer treatment outcomes through personalized medicine.
Features
- Analyzes over 6 million potential mutations across 600+ cancer genes to provide a comprehensive molecular profile.
- Employs computational intelligence to predict patient responses to multiple targeted therapies.
- Delivers a data-backed report that ranks therapies based on predicted efficacy.
- Considers the complex relationships between drugs, targets, genes, and diseases to identify novel therapeutic targets.
- Supports selection of cancer treatment options for healthcare organizations, payers, cancer centers, and labs.
- Validated in clinical trials, demonstrating a 4X higher positive response rate compared to therapies selected based on single biomarkers.